Skip to main content

FDA Approves Quidel's Solana Influenza A, B Assay

NEW YORK (GenomeWeb) – Quidel announced today that it has received US Food and Drug Administration 510(k) approval for its Solana assay for the diagnosis influenza A and B.

The test uses the helicase-dependent amplification technology that underpins Quidel's AmpliVue line of molecular assays, and is designed to detect nucleic acids isolated from nasal and nasopharyngeal swabs from patients with signs and symptoms of respiratory infection. It is intended for use only with the company's Solana instrument.

"A single Solana instrument system performs up to twelve Solana Influenza A+B assays on almost any sample type or brand of viral transport media in under an hour, and up to 96 patient samples during an eight-hour shift, which is critical during an influenza epidemic when testing volumes are at their highest, and samples are coming from several different locations and often collected in a variety of different transported media," Quidel President and CEO Douglas Bryant said in a statement.

The FDA approval comes about a month after the agency cleared Quidel's Solana assay for the sexually transmitted disease trichomoniasis, and a little more than a year after it approved the firm's Solana Group A Streptococcus assay and the Solana platform.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.